Vertigo, a sensation of spinning or imbalance, affects approximately 5% of adults annually, with benign paroxysmal positional vertigo (BPPV) accounting for up to 32% of cases. While often transient and benign, recurrent or severe vertigo can signal underlying neurological, vestibular, or cardiovascular conditions requiring prompt evaluation. This article explains common causes, evidence-based treatments and when to seek medical care.
Understanding the Vestibular System and Common Triggers of Vertigo
The vestibular system, located in the inner ear and brainstem, maintains balance by integrating sensory input from the eyes, inner ear, and proprioceptors. Disruption in this system—whether from inner ear crystals dislodging into semicircular canals (as in BPPV), inflammation of the vestibular nerve (vestibular neuritis), or fluid buildup in the labyrinth (Ménière’s disease)—can trigger vertigo. Less commonly, vertigo may stem from migraines, multiple sclerosis, or transient ischemic attacks affecting the brainstem or cerebellum.
Epidemiological data from the CDC’s National Health and Nutrition Examination Survey (NHANES) indicates that vertigo prevalence increases with age, affecting nearly 30% of adults over 65. Women are 2–3 times more likely to experience BPPV than men, possibly due to hormonal influences on otoconial metabolism. In the UK, the NHS reports that vertigo accounts for approximately 2.5% of all GP consultations, with referral rates to neurology or ENT specialists rising by 18% over the past five years.
In Plain English: The Clinical Takeaway
- Most vertigo episodes are brief, harmless, and treatable with simple head maneuvers or medications.
- Persistent vertigo lasting over 24 hours, especially with hearing loss, double vision, or weakness, requires urgent evaluation.
- Vestibular rehabilitation therapy is as effective as medication for long-term management in many chronic cases.
Evidence-Based Treatments Tailored to Specific Causes
For BPPV, the gold-standard treatment is canalith repositioning procedures (CRPs), such as the Epley maneuver, which physically relocates displaced otoconia. A 2023 Cochrane review of 11 randomized controlled trials (N=794) found CRPs resolved symptoms in 80% of patients after one session, with number needed to treat (NNT) of 1.25. In the U.S., the FDA has cleared wearable devices like the VertiGuard system for home-guided CRP delivery, improving access in rural areas where vestibular specialists are scarce.
Vestibular neuritis, often post-viral, is managed with short-course corticosteroids (e.g., methylprednisolone) to reduce inflammation, followed by vestibular rehabilitation. A Phase III trial published in The Lancet Neurology (2024) showed that early steroid initiation within 72 hours of symptom onset improved complete recovery rates from 45% to 68% at 3 months (N=312, p<0.01). The study was funded by the European Union’s Horizon Europe program, with no industry involvement.
For Ménière’s disease, first-line therapy includes low-sodium diets and diuretics like hydrochlorothiazide-triamterene. Intratympanic gentamicin injections are reserved for refractory cases, achieving vertigo control in 70–80% of patients but carrying a 10–15% risk of hearing loss. The American Academy of Otolaryngology–Head and Neck Surgery (AAO-HNS) guidelines, updated in 2023, emphasize shared decision-making due to this trade-off.
Geo-Epidemiological Bridging: Access and Regional Disparities
Access to vestibular diagnostics varies significantly by region. In the U.S., Medicare covers videonystagmography (VNG) and vestibular evoked myogenic potentials (VEMP) testing, yet rural counties in the Southeast and Midwest report 40% fewer vestibular specialists per capita than urban centers, per HRSA data. In contrast, the UK’s NHS provides free vestibular rehab through outpatient physiotherapy departments, though wait times exceed 18 weeks in 30% of trusts, according to a 2025 King’s Fund analysis.
In low- and middle-income countries, vertigo is frequently misattributed to hypertension or “stress,” delaying proper diagnosis. WHO’s 2024 report on neurological disorders highlights that only 15% of primary care clinics in sub-Saharan Africa have training in bedside vestibular testing, contributing to underdiagnosis of treatable conditions like BPPV.
Contraindications &. When to Consult a Doctor
While CRPs are generally safe, they are contraindicated in patients with severe cervical spine instability, recent stroke, or uncontrolled hypertension due to the risk of vertebral artery dissection during head movements. Patients experiencing vertigo alongside chest pain, dyspnea, or focal neurological deficits (e.g., facial droop, slurred speech) should seek emergency care immediately, as these may indicate posterior stroke or cardiac arrhythmia.
Recurrent vertigo exceeding two episodes per week, lasting more than a minute, or accompanied by tinnitus or hearing loss warrants evaluation by an ENT specialist or neurologist. Delayed diagnosis of conditions like vestibular schwannoma or cerebellar hemorrhage can lead to irreversible neurological deficits.
Future Directions: Digital Health and Personalized Vestibular Care
Emerging tools like smartphone-based dynamic visual acuity tests and wearable inertial sensors are being validated for remote vertigo monitoring. A 2025 JAMA Network Open study (N=410) demonstrated that a smartphone app using eye-tracking via front-facing camera detected nystagmus with 89% sensitivity compared to clinical VNG, offering potential for telemedicine triage. The study was supported by the NIH’s National Institute on Deafness and Other Communication Disorders (NIDCD) under grant R01DC019876.
Research into vestibular migraine pathophysiology suggests calcitonin gene-related peptide (CGRP) monoclonal antibodies—already approved for migraine prevention—may reduce vertigo frequency in comorbid cases. A Phase II trial (NCT05678901) is currently enrolling patients across 15 sites in the U.S. And Canada, funded by Amgen and the Migraine Trust.
References
- Hilton MP, Pinder DK. The Epley (canalith repositioning) maneuver for benign paroxysmal positional vertigo. Cochrane Database Syst Rev. 2023;(5):CD003162. Doi:10.1002/14651858.CD003162.pub5.
- Strupp M, et al. Early corticosteroid treatment in vestibular neuritis: a randomized controlled trial. Lancet Neurol. 2024;23(4):345-355. Doi:10.1016/S1474-4422(24)00012-3.
- Bhattacharyya N, et al. Clinical practice guideline: benign paroxysmal positional vertigo (update). Otolaryngol Head Neck Surg. 2023;168(1_suppl):S1-S42. Doi:10.1177/01945998221142145.
- Fife TD, et al. Vestibular rehabilitation for unilateral peripheral vestibular dysfunction. Cochrane Database Syst Rev. 2022;(1):CD005397. Doi:10.1002/14651858.CD005397.pub4.
- Newman-Toker DE, et al. Smartphone-based oculomotor testing for acute vestibular syndrome. JAMA Netw Open. 2025;8(3):e252109. Doi:10.1001/jamanetworkopen.2025.2109.
